metronidazole has been researched along with Cholangitis, Sclerosing in 6 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to compare interventions in terms of patient mortality or liver transplantation (MOLT), progression of liver histological stage (POLHS), serum bilirubin, alkaline phosphatase (ALP) levels and adverse events (AE)." | 2.52 | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. ( Braddock, M; Chen, YP; Huang, GQ; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH; Zhou, MT; Zhu, GQ, 2015) |
| "One of them also had primary sclerosing cholangitis." | 2.42 | [Pancreatitis accompanying inflammatory bowel diseases, and our observations]. ( Aleksandrova, A; Nedin, D, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferstl, PG | 1 |
| Reinheimer, C | 1 |
| Jozsa, K | 1 |
| Zeuzem, S | 1 |
| Kempf, VA | 1 |
| Waidmann, O | 1 |
| Grammatikos, G | 1 |
| Paterson, JC | 1 |
| Dillon, JF | 1 |
| Zhu, GQ | 1 |
| Shi, KQ | 1 |
| Huang, GQ | 1 |
| Wang, LR | 1 |
| Lin, YQ | 1 |
| Braddock, M | 1 |
| Chen, YP | 1 |
| Zhou, MT | 1 |
| Zheng, MH | 1 |
| Tabibian, JH | 1 |
| Weeding, E | 1 |
| Jorgensen, RA | 1 |
| Petz, JL | 1 |
| Keach, JC | 1 |
| Talwalkar, JA | 1 |
| Lindor, KD | 1 |
| Färkkilä, M | 1 |
| Karvonen, AL | 1 |
| Nurmi, H | 1 |
| Nuutinen, H | 1 |
| Taavitsainen, M | 1 |
| Pikkarainen, P | 1 |
| Kärkkäinen, P | 1 |
| Nedin, D | 1 |
| Aleksandrova, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis[NCT01085760] | Phase 1 | 35 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01085760)
Timeframe: baseline, 12 weeks
| Intervention | U/L (Median) |
|---|---|
| Low Dose Vancomycin | -117 |
| High Dose Vancomycin | -49 |
| Low Dose Metronidazole | -62 |
| High Dose Metronidazole | -36 |
(NCT01085760)
Timeframe: baseline, 12 weeks
| Intervention | mg/L (Median) |
|---|---|
| Low Dose Vancomycin | -2.2 |
| High Dose Vancomycin | 1 |
| Low Dose Metronidazole | -3.6 |
| High Dose Metronidazole | 0 |
The Mayo PSC risk score was calculated for each patient at baseline and at 12 weeks, where Risk = 0.03 (age [years]) + 0.54 Ln (total bilirubin [mg/dL]) + 0.54 Ln (AST [IU/L]) + 1.24 (variceal bleeding) - 0.84 (albumin [g/dL]). There is no range, minimum, or maximum value but greater values indicate worse disease. (NCT01085760)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Low Dose Vancomycin | -0.65 |
| High Dose Vancomycin | -0.01 |
| Low Dose Metronidazole | -0.26 |
| High Dose Metronidazole | -0.20 |
(NCT01085760)
Timeframe: baseline, 12 weeks
| Intervention | mg/dl (Median) |
|---|---|
| Low Dose Vancomycin | -0.4 |
| High Dose Vancomycin | 0.05 |
| Low Dose Metronidazole | -0.3 |
| High Dose Metronidazole | 0.05 |
2 reviews available for metronidazole and Cholangitis, Sclerosing
| Article | Year |
|---|---|
A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cholangitis, Sclerosing; | 2015 |
[Pancreatitis accompanying inflammatory bowel diseases, and our observations].
Topics: Acute Disease; Amylases; Anti-Infective Agents; Anti-Inflammatory Agents; Bulgaria; Cholangitis, Scl | 2004 |
2 trials available for metronidazole and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bilirubin; Biomarkers; Cholangitis, Sclerosing; Dose-Response Re | 2013 |
Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Topics: Adult; Anti-Infective Agents; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retr | 2004 |
2 other studies available for metronidazole and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Severe infection with multidrug-resistant
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cholangiopancreatography, Endoscopic Retrograde; Chol | 2017 |
Commentary: vancomycin or metronidazole in patients with primary sclerosing cholangitis?
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Female; Humans; Male; Metronidazole; Vancomycin | 2013 |